## SYK: Stryker Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.0% below STRENGTH zone (3.0-6.0%); PEG 1.46 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($341.23)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Stryker Utah expansion expected to bring over $615M in investments, 862 new jobs**
- Source: KSL.com | 20251216T021535 | Bullish | Relevance: 100%
- Medical technology company Stryker announced a significant expansion of its Salt Lake City operations, projecting over $615 million in investments and the creation of 862 new jobs over the next two decades. This growth is supported by a post-performance tax reduction from Utah's Economic Development Tax Increment Financing program, highlighting the state's talent pool and innovation-friendly environment. The expansion is celebrated by local officials as a boost for Salt Lake City families and the regional economy, reinforcing the city's role as a hub for medical technology advancements.

**2. Corient Private Wealth LLC Increases Stake in Stryker Corporation $SYK**
- Source: MarketBeat | 20251215T095935 | Bullish | Relevance: 100%
- Corient Private Wealth LLC significantly increased its holdings in Stryker Corporation (NYSE:SYK) by 2.6% in the second quarter, bringing its total stake to 1,127,559 shares valued at approximately $446.1 million. This makes Stryker the 24th largest holding for Corient. Other major institutional investors, including Vanguard Group Inc. and State Street Corp, also increased their positions, while company insiders have sold a considerable number of shares recently.

**3. Stryker (NYSE:SYK) Has Announced That It Will Be Increasing Its Dividend To $0.88**
- Source: Simply Wall Street | 20251214T140801 | Bullish | Relevance: 100%
- Stryker Corporation (NYSE:SYK) has announced an increase in its periodic dividend to $0.88, effective January 30th, representing a 4.8% rise from the previous year. Although the dividend yield is relatively low at 0.9%, the payment is well-covered by earnings, with a projected payout ratio of 25% by next year. The company has a solid track record of consistent dividend growth and strong earnings per share, making it an attractive income stock.

**4. Stryker (NYSE:SYK) Downgraded by Wall Street Zen to Hold**
- Source: MarketBeat | 20251214T040832 | Neutral | Relevance: 100%
- Wall Street Zen downgraded Stryker (NYSE:SYK) from a "buy" to a "hold" rating, though the consensus remains a "Moderate Buy" with a target price of $431.83. This follows Stryker beating Q3 expectations with $3.19 EPS and $6.06B revenue, and setting optimistic FY2025 guidance. Despite the positive financial performance, there has been significant insider selling, with over 500,000 shares sold by company insiders in the last quarter.

**5. Stryker (SYK) Stock This Week: Dividend Hike, New COO, FDA Recall Watchlist â€” Outlook for the Week Ahead (Updated Dec. 12, 2025)**
- Source: ts2.tech | 20251213T050823 | Somewhat-Bullish | Relevance: 100%
- Stryker (SYK) experienced a volatile week, closing at $354.09, down 2.7%. Key developments included a dividend hike to $0.88 per share, the appointment of Spencer Stiles as President and COO, and an FDA Class I recall watch for a TMJ Bilateral Implant. Analysts remain broadly bullish despite Citigroup trimming its price target, while investors will monitor macro trends and company-specific updates next week.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-11 | Citigroup | $420 | $455 | -8% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-11 | Citigroup | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 6 ($34.68M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 40.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 8.8% (+0.8%)
- Blackrock Inc.: 7.0% (+0.4%)
- JPMORGAN CHASE & CO: 6.2% (+95.3%)
- Greenleaf Trust: 4.3% (-0.3%)
- State Street Corpora: 3.9% (-0.1%)

### Key Risks

1. Heavy insider selling: $35M sold (6 transactions in 90 days).
2. Long-term trend broken: trading 5.5% below SMA200.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Momentum building: MRS_10 improving +6.2% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.46 suggests fair value with growth premium. Forward P/E 23.8x stretched relative to 10% growth. Balance sheet: $1.4B free cash flow. Analyst sentiment negative (1 target cuts vs 0 raises). Insider selling cluster ($34.7M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $135.9B |
| Beta | 0.90 |
| 52W Range | $329.16 - $406.19 |
| Short Interest | 1.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.46 |
| Forward P/E | 23.8 |
| Current P/E | 26.2 |
| YoY Growth | 10.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -5.2% to 1.0% (+6.2% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.0pp (needs >3.0% for momentum thesis). MRS_5 at 2.2% confirms short-term momentum alignment. Below SMA200 (0.94x), long-term trend not supportive. MACD histogram bearish (-1.18), momentum weakening. RSI neutral at 42. OFD pattern: +SLN (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.96% (CS: 35) | Neutral |
| RSI_14 | 42.1 | Neutral |
| MACD Histogram | -1.18 | Bearish |
| vs SMA20 | 0.980x | Below |
| vs SMA50 | 0.969x | Below |
| vs SMA200 | 0.945x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $355.31
- **Stop Loss:** $341.23 (4.0% risk)
- **Target:** $369.39 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 85
- **Position Value:** $30,201.35
- **Portfolio %:** 30.20%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at moderate levels (16.5) with elevated put/call ratio suggesting cautious positioning, while normal yield curve and stable breadth indicate no systemic stress. Focus on selective opportunities with defensive positioning.*

### Earnings

**Next:** 2026-01-27 (Est: $4.39)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.13 | $3.19 | +1.9% |
| 2025Q2 | $3.07 | $3.13 | +1.9% |
| 2025Q1 | $2.73 | $2.84 | +4.0% |
| 2024Q4 | $3.87 | $4.01 | +3.5% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*